Reviewing the role of donepezil in the treatment of Alzheimer's disease

Current Alzheimer Research

Volumn 9, Issue 7, 2012, Pages 773-781

  Doody, Rachelle S ^a   Cummings, Jeffrey L ^b   Farlow, Martin R ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease; Donepezil; Mild cognitive impairment; Mild to moderate Alzheimer's disease; Moderate severe to severe Alzheimer's disease

Indexed keywords

BIOLOGICAL MARKER; DONEPEZIL; MEMANTINE; PLACEBO;

ADL DISABILITY; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; BECK DEPRESSION INVENTORY; BRAIN BLOOD FLOW; BRAIN SIZE; CHOLINERGIC NERVE CELL; CHOLINERGIC TRANSMISSION; CLINICAL DEMENTIA RATING SCALE SUM OF THE BOXES; CLINICIAN INTERVIEW BASED IMPRESSION OF CHANGE WITH CAREGIVER INPUT; DAILY LIFE ACTIVITY; DIARRHEA; DISABILITY ASSESSMENT FOR DEMENTIA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FUNCTIONAL NEUROIMAGING; FUNCTIONAL RATING SCALE; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NAUSEA; NERVE CELL NECROSIS; NEUROPSYCHIATRIC INVENTORY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; SEVERE IMPAIRMENT BATTERY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VOMITING;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DEMENTIA; HUMANS; INDANS; NOOTROPIC AGENTS; PIPERIDINES;

EID: 84866669849     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512802455412     Document Type: Article

References (68)

1. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 362(4): 329-344 (2010).
2. Kasai M, Nakamura K, Meguro K. Alzheimer's disease in Japanand other countries: review of epidemiological studies in the last 10years. Brain Nerve 62(7): 667-678 (2010).
3. Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, Ferris SH, F et al. Diagnosis and treatment of Alzheimer diseaseand related disorders. Consensus statement of the American Associationfor Geriatric Psychiatry, the Alzheimer's Association, andthe American Geriatrics Society. JAMA 278(16): 1363-1371(1997).
4. Bird TD. Genetic aspects of Alzheimer disease. Genet Med 10(4):231-239 (2008).
5. Davies P, Maloney A. Selective loss of central cholinergic neuronsin Alzheimer's disease [letter]. Lancet 2(8000): 1403 (1976).
6. Perry EK, Perry RH, Blessed G, Tomlinson BE. Necropsy evidenceof central cholinergic deficits in senile dementia. Lancet 1(8004):189 (1977).
7. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence for selective loss of cholinergic neuronsin the nucleus basalis. Ann Neurol 10(2): 122-126 (1981).
8. Perry EK, Blessed G, Tomlinson BE, Perry RH, Crow TJ, CrossAJ, et al. Neurochemical activities in human temporal lobe relatedto aging and Alzheimer-type changes. Neurobiol Aging 2(4): 251-256 (1981).
9. Inestrosa NC, Alvarez A, Pérez CA, Moreno RD, Vicente M, LinkerC, et al. Acetylcholinesterase accelerates assembly of amyloid-peptides into Alzheimer's fibrils: possible role of the peripheralsite of the enzyme. Neuron 16(4): 881-891 (1996).
10. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". Apractical method for grading the cognitive state of patients for theclinician. J Psychiatr Res 12(3): 189-198 (1975).
11. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, the DonepezilStudy Group. Donepezil improves cognition and global function inAlzheimer disease: a 15-week, double-blind, placebo-controlledstudy. Arch Intern Med 158(9): 1021-1031 (1998).
12. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, DonepezilStudy Group. A 24-week, double-blind, placebo-controlledtrial of donepezil in patients with Alzheimer's disease. Neurology50(1): 136-145 (1998).
13. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, et al. A double-blind, placebo-controlled multicenter study oftacrine for Alzheimer's disease. The Tacrine Collaborative StudyGroup. N Engl J Med 327(18): 1253-1259 (1992).
14. Farlow M, Gracon S, Hershey L, Lewis K, Sadowsky C, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. TheTacrine Study Group. JAMA 268(18): 2523-2529 (1992).
15. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer'sdisease. Am J Psychiatry 141: 1356-1364 (1984).
16. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, ReisbergB, et al. Validity and reliability of the Alzheimer's Disease CooperativeStudy-Clinical Global Impression of Change. The Alzheimer'sDisease Cooperative Study. Alzheimer Dis Assoc Disord11(Suppl 2): S22-S32 (1997).
17. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A newclinical scale for the staging of dementia. Br J Psychiatry 140: 566-572 (1982).
18. Morris JC. The Clinical Dementia Rating (CDR): current versionand scoring rules. Neurology 43(11): 2412-2414 (1993).
19. Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD, forthe Donepezil Study Group. Open-label, multicenter, phase 3 extensionstudy of the safety and efficacy of donepezil in patientswith Alzheimer disease. Arch Neurol 58: 427-433 (2001).
20. Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy andsafety of donepezil in the treatment of Alzheimer's disease: finalanalysis of a US multicentre open-label study. Eur Neuropsychopharmacol10: 195-203 (2000).
21. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, PerdomoCA, et al. A 1-year, placebo-controlled preservation of functionsurvival study of donepezil in AD patients [published erratum appearsin Neurology. 2001;57:1942]. Neurology 57(3): 481-488(2001).
22. Winblad B, Wimo A, Engedal K, Soininen H, Verhey F, WaldemarG, et al. 3-Year study of donepezil therapy in Alzheimer's disease:effects of early and continuous therapy. Dement Geriatr CognDisord 21: 353-363 (2006).
23. Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D, Ieni J, etal. Efficacy of donepezil in early-stage Alzheimer disease: a randomizedplacebo-controlled trial. Arch Neurol 61(12): 1852-1856(2004).
24. Petersen RC. Mild cognitive impairment as a diagnostic entity. JIntern Med 256(3): 183-194 (2004).
25. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mildcognitive impairment. Alzheimer's Disease Cooperative StudyGroup. N Engl J Med 352(23): 2379-2388 (2005).
26. Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, et al. Efficacy of donepezil in mild cognitive impairment: a randomizedplacebo-controlled trial. Neurology 63(4): 651-657(2004).
27. Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, WatkinsWE, et al. Donepezil treatment of patients with MCI: a 48-weekrandomized, placebo-controlled trial. Neurology 72(18): 1555-1561(2009).
28. Lu PH, Edland SD, Teng E, Tingus K, Petersen RC, Cummings JL. Donepezil delays progression to AD in MCI subjects with depressivesymptoms. Neurology 72(24): 2115-2121 (2009).
29. Doody RS, Ferris S, Salloway S, Yijun Sun, Goldman R, YikangXu, et al. Safety and tolerability of donepezil in mild cognitive impairment:open-label extension study. Am J Alzheimers Dis OtherDemen 25(2): 155-159 (2010).
30. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderateto severe Alzheimer's disease. Neurology 57(4): 613-620(2001).
31. Panisset M, Roudier M, Saxton J, Boller F. Severe impairmentbattery. A neuropsychological test for severely demented patients. Arch Neurol 51(1): 41-45 (1994).
32. Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of afunctional measure for persons with Alzheimer's disease: the disabilityassessment for dementia. Am J Occup Ther 53(5): 471-481(1999).
33. Feldman H, Schulzer M, Wang S, Tuokko H, Beattie BL. Thefunctional rating scale in Alzheimer's disease assessment: a longitudinalstudy. In: Research advances in Alzheimer's disease and relateddisorders. 1st ed. (Eds: Iqbal K, Mortimer JA, Winblad B, Wisniewski H). Chichester: John Wiley and Sons Ltd. pp 235-241(1995).
34. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, CarusiDA, Gornbein J. The Neuropsychiatric Inventory: comprehensiveassessment of psychopathology in dementia. Neurology 44(12):2308-2314 (1994).
35. Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, et al. Efficacy and safety of donepezil in patients with more severe Alzheimer'sdisease: a subgroup analysis from a randomized, placebocontrolledtrial. Int J Geriatr Psychiatry 20(6): 559-569 (2005).
36. Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, et al. Donepezil preserves cognition and global function in patients withsevere Alzheimer disease. Neurology 69(5): 459-469 (2007).
37. Homma A, Imai Y, Tago H, Asada T, Shigeta M, Iwamoto T, et al. Donepezil treatment of patients with severe Alzheimer's disease ina Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord25(5): 399-407 (2008).
38. Winblad B, Kilander L, Eriksson S, Minthon L, Båtsman S, WetterholmAL, et al. Donepezil in patients with severe Alzheimer'sdisease: double-blind, parallel-group, placebo-controlled study. Lancet 367(9516): 1057-1065 (2006).
39. Galasko D, Bennett D, Sano M, et al. An inventory to assess activitiesof daily living for clinical trials in Alzheimer's disease. TheAlzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord11(Suppl 2): S33-S39 (1997).
40. Winblad B, Black SE, Homma A, Schwam EM, Moline M, Xu Y, et al. Donepezil treatment in severe Alzheimer's disease: a pooledanalysis of three clinical trials. Curr Med Res Opin 25: 2577-2587(2009).
41. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Möbius HJ, et al. Memantine in moderate-to-severe Alzheimer's disease. NEngl J Med 348(14): 1333-1341 (2003).
42. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, et al. Memantine treatment in patients with moderate tosevere Alzheimer disease already receiving donepezil: a randomizedcontrolled trial. JAMA 291(3): 317-324 (2004).
43. Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA. Limited donepezil inhibition of acetylcholinesterasemeasured with positron emission tomography in living Alzheimercerebral cortex. Ann Neurol 48(3): 391-395 (2000).
44. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Koeppe RA, et al. Degree of inhibition of cortical acetylcholinesteraseactivity and cognitive effects by donepezil treatment inAlzheimer's disease. J Neurol Neurosurg Psychiatry 76(3): 315-319(2005).
45. Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R. Safety and tolerability of donepezil at doses up to 20 mg/day: resultsfrom a pilot study in patients with Alzheimer's disease. DrugsAging 25(2): 163-174 (2008).
46. Farlow M, Salloway S, Tariot P, Yardley J, Moline ML, Wang Q, et al. Double-blind, randomized 24-week study comparing the efficacyand safety of donepezil 23 mg to donepezil 10 mg in moderateto severe Alzheimer disease. Clin Ther 32: 1234-1251 (2010).
47. Doody RS. We should not distinguish between symptomatic anddisease-modifying treatments in Alzheimer's disease drug development. Alzheimers Dement 4(1 Suppl 1): S21-S25 (2008).
48. Francis PT, Nordberg A, Arnold SE. A preclinical view of cholinesteraseinhibitors in neuroprotection: do they provide more thansymptomatic benefits in Alzheimer's disease? Trends PharmacolSci 26(2): 104-111 (2005).
49. Akasofu S, Kosasa T, Kimura M, Kubota A. Protective effect ofdonepezil in a primary culture of rat cortical neurons exposed tooxygen-glucose deprivation. Eur J Pharmacol 472(1-2): 57-63(2003).
50. Zhou J, Fu Y, Tang XC. Huperzine A and donepezil protect ratpheochromocytoma cells against oxygen-glucose deprivation. NeurosciLett 306(1-2): 53-56 (2001).
51. Takada Y, Yonezawa A, Kume T, Katsuki H, Kaneko S, SugimotoH, et al. Nicotinic acetylcholine receptor-mediated neuroprotectionby donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther 306(2): 772-777 (2003).
52. Svensson AL, Nordberg A. Tacrine and donepezil attenuate theneurotoxic effect of A beta(25-35) in rat PC12 cells. Neuroreport9(7): 1519-1522 (1998).
53. Lahiri DK, Greig NH, Farlow MR. Regulation of APP processingwith cholinesterase inhibitors. Res Pract Alzheimers Dis 5: 27-32(2001).
54. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimeramyloid precursor derivatives stimulated by activation ofmuscarinic acetylcholine receptors. Science 258(5080): 304-307(1992).
55. Staff RT, Gemmell HG, Shanks MF, Murray AD, Venneri A. Changes in the rCBF images of patients with Alzheimer's diseasereceiving donepezil therapy. Nucl Med Commun 21(1): 37-41(2000).
56. Nobili F, Vitali P, Canfora M, Girtler N, De Leo C, Mariani G, etal. Effects of long-term donepezil therapy on rCBF of Alzheimer'spatients. Clin Neurophysiol 113(8): 1241-1248 (2002).
57. Hoyer S. Oxidative energy metabolism in Alzheimer brain. Studiesin early-onset and late-onset cases. Mol Chem Neuropathol 16(3):207-224 (1992).
58. Meltzer CC, Zubieta JK, Brandt J, Tune LE, Mayberg HS, Frost JJ. Regional hypometabolism in Alzheimer's disease as measured bypositron emission tomography after correction for effects of partialvolume averaging. Neurology 47(2): 454-461 (1996).
59. Tune L, Tiseo PJ, Ieni J, Perdomo C, Pratt RD, Votaw JR, et al. Donepezil HCl (E2020) maintains functional brain activity in patientswith Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry 11(2): 169-177(2003).
60. Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, et al. Randomized, placebo-controlled trial of the effects ofdonepezil on neuronal markers and hippocampal volumes in Alzheimer'sdisease. Am J Psychiatry 160(11): 2003-2011 (2003).
61. Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, MoriE. Does donepezil treatment slow the progression of hippocampalatrophy in patients with Alzheimer's disease? Am J Psychiatry162(4): 676-682 (2005).
62. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement inpatients with Alzheimer's disease. J Am Geriatr Soc 51(7): 937-944(2003).
63. Jones RW, Schwam E, Wilkinson D, Waldemar G, Feldman HH, Zhang R, et al. Rates of cognitive change in Alzheimer disease: observationsacross a decade of placebo-controlled clinical trials withdonepezil. Alzheimer Dis Assoc Disord 23(4): 357-364 (2009).
64. Wilkinson D, Schindler R, Schwam E, Waldemar G, Jones RW, Gauthier S, et al. Effectiveness of donepezil in reducing clinicalworsening in patients with mild-to-moderate Alzheimer's disease. Dement Geriatr Cogn Disord 28(3): 244-251 (2009).
65. Lopez OL, Schwam E, Cummings J, Gauthier S, Jones R, WilkinsonD, et al. Predicting cognitive decline in Alzheimer's disease: anintegrated analysis. Alzheimers Dement 6(6): 431-439 (2010).
66. Waldemar G, Gauthier S, Jones R, Wilkinson D, Cummings J, Lopez O, et al. Effect of donepezil on emergence of apathy in mildto moderate Alzheimer's disease. Int J Geriatr Psychiatry 26(2):150-157 (2011).
67. Gauthier S, Lopez OL, Waldemar G, Jones RW, Cummings J, Zhang R, et al. Effects of donepezil on activities of daily living: integratedanalysis of patient data from studies in mild, moderate andsevere Alzheimer's disease. Int Psychogeriatr 22(6): 973-983(2010).
68. Cummings J, Jones R, Wilkinson D, Lopez O, Gauthier S, WaldemarG, et al. Effect of donepezil on cognition in severe Alzheimer'sdisease: a pooled data analysis. J Alzheimers Dis 21(3): 843-851(2010).